U.S. Health Secretary Robert F. Kennedy Jr. announced plans to reform the National Vaccine Injury Compensation Program (VICP), pledging to address what he calls inefficiencies and corruption within the system. Kennedy, a long-time vaccine skeptic and former vaccine injury lawyer, criticized the program’s “Vaccine Court” for failing to quickly and fairly compensate individuals harmed by vaccines.
In a post on X, Kennedy said he is working with Attorney General Pam Bondi to restore the program to its “original congressional intent,” arguing that its current structure unfairly positions the Department of Health and Human Services (HHS), which he leads, as the defendant rather than vaccine manufacturers.
This move continues Kennedy’s sweeping efforts to reshape U.S. vaccine and health policy. In June, he dismissed all 17 members of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, replacing them with seven appointees, including figures with histories of questioning vaccine safety. One of these members previously earned significant fees as an expert witness against Merck’s Gardasil vaccine, a case in which Kennedy played a key role.
Kennedy is also reportedly considering removing members of another influential health advisory panel, the U.S. Preventive Services Task Force. His tenure at HHS has intensified scrutiny due to his longstanding promotion of vaccine skepticism, including discredited claims linking vaccines to autism and false statements about fetal cells in the measles vaccine.
The announcement comes amid one of the worst U.S. measles outbreaks in decades, further fueling debate over vaccine safety, public health policy, and Kennedy’s leadership approach.


Trump Administration Sued Over Suspension of Critical Hudson River Tunnel Funding
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Norway Opens Corruption Probe Into Former PM and Nobel Committee Chair Thorbjoern Jagland Over Epstein Links
Trump Allegedly Sought Airport, Penn Station Renaming in Exchange for Hudson River Tunnel Funding
Paul Atkins Emphasizes Global Regulatory Cooperation at Fintech Conference
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Pentagon Ends Military Education Programs With Harvard University
US Pushes Ukraine-Russia Peace Talks Before Summer Amid Escalating Attacks
Trump Threatens 50% Tariff on Canadian Aircraft Amid Escalating U.S.-Canada Trade Dispute
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 



